

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

NCT06864013

Status	RECRUITING
Phase	Phase 2
Sponsor	First Affiliated Hospital of Zhejiang University
Enrollment	116 participants

Key Eligibility Criteria

Inclusion (14)

- Sign a written Informed Consent Form (ICF) and be able to comply with the visits and related procedures stipulated in the protocol
- Age between 18 and 75 years old
- Histologically confirmed rectal adenocarcinoma
- According to the AJCC 8th Edition staging, imaging evaluation (enhanced CT or enhanced MRI) confirms resectable locally advanced rectal cancer (AJCC 8th Edition staging cT3-4 / cN+)
- Patients with microsatellite stability (MSS) or proficient mismatch repair (pMMR) rectal cancer
- ... and 9 more (see full listing online)

Exclusion (40)

- Patients with rectal cancer who have been tested for microsatellite instability as MSI-H or mismatch repair as dMMR
- Patients who have previously received any anti-tumor treatment for the studied disease, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. This includes previous treatment with anti-PD-1, anti-PD-L1, anti-programmed death receptor ligand 2 (PD-L2) or anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) drugs, or any other drugs acting on T cell co-stimulation or immune checkpoint pathways (such as OX40, CD137, etc.), as well as adoptive cell immunotherapy
- Simultaneous participation in another clinical study, unless participating in an observational (non-interventional) clinical study or in the survival follow-up phase of an interventional study
- Treatment with any investigational drug or device within 4 weeks prior to the first dose of the study drug
- History of blood transfusion within 14 days before the screening laboratory tests, or use of Granulocyte-colony stimulating factor (G-CSF), Granulocyte-Macrophage-colony stimulating factor (GM-CSF), erythropoietin (EPO), thrombopoietin (TPO), or IL-11
- ... and 35 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

<https://clinicaltrials.gov/study/NCT06864013>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).